CNMD vs. INMD, SLNO, LIVN, BLFS, ITGR, TMDX, MASI, RXST, VERA, and ASTH
Should you be buying CONMED stock or one of its competitors? The main competitors of CONMED include InMode (INMD), Soleno Therapeutics (SLNO), LivaNova (LIVN), BioLife Solutions (BLFS), Integer (ITGR), TransMedics Group (TMDX), Masimo (MASI), RxSight (RXST), Vera Therapeutics (VERA), and Astrana Health (ASTH). These companies are all part of the "medical" sector.
CONMED (NYSE:CNMD) and InMode (NASDAQ:INMD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
CONMED currently has a consensus price target of $107.86, suggesting a potential upside of 44.35%. InMode has a consensus price target of $32.80, suggesting a potential upside of 77.68%. Given InMode's higher possible upside, analysts plainly believe InMode is more favorable than CONMED.
In the previous week, InMode had 1 more articles in the media than CONMED. MarketBeat recorded 6 mentions for InMode and 5 mentions for CONMED. CONMED's average media sentiment score of 0.96 beat InMode's score of 0.87 indicating that CONMED is being referred to more favorably in the media.
InMode received 132 more outperform votes than CONMED when rated by MarketBeat users. Likewise, 75.12% of users gave InMode an outperform vote while only 42.37% of users gave CONMED an outperform vote.
68.0% of InMode shares are owned by institutional investors. 6.8% of CONMED shares are owned by insiders. Comparatively, 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CONMED has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, InMode has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.
InMode has a net margin of 38.84% compared to CONMED's net margin of 6.53%. InMode's return on equity of 26.15% beat CONMED's return on equity.
InMode has lower revenue, but higher earnings than CONMED. InMode is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats CONMED on 12 of the 18 factors compared between the two stocks.
Get CONMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
